Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dorzagliatin (HMS5552) is a dual-acting glucokinase (GK) activator. It also improves glycaemic control and pancreatic β-cell function in type 2 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 79.00 | |
10 mg | In stock | $ 125.00 | |
25 mg | In stock | $ 253.00 | |
50 mg | In stock | $ 397.00 | |
100 mg | In stock | $ 597.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 87.00 |
Description | Dorzagliatin (HMS5552) is a dual-acting glucokinase (GK) activator. It also improves glycaemic control and pancreatic β-cell function in type 2 diabetes. |
In vivo | In diabetic rats, Dorzagliatin (low-dose 10?mg/kg, and high-dose 30?mg/kg; administered intragastrically; daily 8:00 AM for one month) shows a glucose-lowering effect on the glucose levels[2]. |
Synonyms | HMS5552 |
Molecular Weight | 462.93 |
Formula | C22H27ClN4O5 |
CAS No. | 1191995-00-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (270.02 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dorzagliatin 1191995-00-2 Metabolism Glucokinase HMS5552 diabetes inhibit β-cell Hexokinase IV Inhibitor glycaemic type 2 Hexokinase D pancreatic HMS-5552 HMS 5552 inhibitor